Association Between Metabolic Risk Factors and Cognitive Impairment in Schizophrenia Based on Sex
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective Sex differences have been observed in many aspects of schizophrenia, including cognitive deficits. Despite extensive research into the relationship between metabolic factors and cognitive deficits in schizophrenia, few studies have explored the potential sex difference in their association.Methods We recruited 358 schizophrenia patients and 231 healthy controls. The participants underwent measurements of body mass index (BMI), waist circumference, blood pressure, triglycerides, high-density lipoprotein cholesterol, and fasting blood glucose. Metabolic risk factors included abdominal obesity, hypertension, hyperglycemia, and dyslipidemia. A collection of these metabolic risk factors has been defined as metabolic syndrome. These diagnoses were based on the criteria of the National Cholesterol Education Program’s Adult Treatment Panel III. Cognitive performance was measured using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). A descriptive analysis, difference analysis, and linear regression model were used to identify the metabolic risk factors for cognitive function in schizophrenia.Results Our findings revealed sex differences in the rate of abdominal obesity and hypertension in schizophrenic patients. Additionally, we observed sex differences in the association between metabolic risk factors and cognitive impairment in schizophrenia. Specifically, hyperglycemia was associated with the immediate memory index score of RBANS in male patients, while dyslipidemia was associated with language, attention, delayed memory index scores, and RBANS total score in female patients.Conclusion Our results suggest that sex should be considered when evaluating the impact of metabolic disorders on the cognitive function of schizophrenic patients. Moreover, our study identifies hyperglycemia and dyslipidemia as potential targets for precise treatment by sex stratification, which could benefit the improvement of cognitive impairment in schizophrenic patients.
Abstract
Objective Sex differences have been observed in many aspects of schizophrenia, including cognitive deficits. Despite extensive research into the relationship between metabolic factors and cognitive deficits in schizophrenia, few studies have explored the potential sex difference in their association.Methods We recruited 358 schizophrenia patients and 231 healthy controls. The participants underwent measurements of body mass index (BMI), waist circumference, blood pressure, triglycerides, high-density lipoprotein cholesterol, and fasting blood glucose. Metabolic risk factors included abdominal obesity, hypertension, hyperglycemia, and dyslipidemia. A collection of these metabolic risk factors has been defined as metabolic syndrome. These diagnoses were based on the criteria of the National Cholesterol Education Program’s Adult Treatment Panel III. Cognitive performance was measured using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). A descriptive analysis, difference analysis, and linear regression model were used to identify the metabolic risk factors for cognitive function in schizophrenia.Results Our findings revealed sex differences in the rate of abdominal obesity and hypertension in schizophrenic patients. Additionally, we observed sex differences in the association between metabolic risk factors and cognitive impairment in schizophrenia. Specifically, hyperglycemia was associated with the immediate memory index score of RBANS in male patients, while dyslipidemia was associated with language, attention, delayed memory index scores, and RBANS total score in female patients.Conclusion Our results suggest that sex should be considered when evaluating the impact of metabolic disorders on the cognitive function of schizophrenic patients. Moreover, our study identifies hyperglycemia and dyslipidemia as potential targets for precise treatment by sex stratification, which could benefit the improvement of cognitive impairment in schizophrenic patients.
참고문헌 (53)
- Marder SR, "Schizophrenia", N Engl J Med, 381, pp.1753~1761 (2019)
- Kahn RS, "Schizophrenia", Nat Rev Dis Primers, 1, pp.15067~ (2015)
- Zhu MH, "Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia : a 12-week randomized, double-blind, placebo-controlled trial", Mil Med Res, 9, pp.59~ (2022)
- Qiu C, "A major role for cardiovascular burden in age-related cognitive decline", Nat Rev Cardiol, 12, pp.267~277 (2015)
- van den Berg E, "Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity : a systematic comparison of their impact on cognition", Biochim Biophys Acta, 1792, pp.470~481 (2009)
- Kassi E, "Metabolic syndrome : definitions and controversies", BMC Med, 9, pp.48~ (2011)
- Kouvari M, "Metabolic syndrome, cognitive impairment and the role of diet : a narrative review", Nutrients, 14, pp.333~ (2022)
- Vancampfort D, "A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls", World Psychiatry, 12, pp.240~250 (2013)
- Grover S, "Relationship of metabolic syndrome and neurocognitive deficits in patients with schizophrenia", Psychiatry Res, 278, pp.56~64 (2019)
- Friedman JI, "The effects of hypertension and body mass index on cognition in schizophrenia", Am J Psychiatry, 167, pp.1232~1239 (2010)
- Takayanagi Y, "Diabetes is associated with lower global cognitive function in schizophrenia", Schizophr Res, 142, pp.183~187 (2012)
- Depp CA, "Association of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia", Bipolar Disord, 16, pp.422~431 (2014)
- Hagi K, "Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia : a systematic review and metaanalysis", JAMA Psychiatry, 78, pp.510~518 (2021)
- Vanhanen M, "Association of metabolic syndrome with Alzheimer disease : a population-based study", Neurology, 67, pp.843~847 (2006)
- Schuur M, "Insulin-resistance and metabolic syndrome are related to executive function in women in a large family-based study", Eur J Epidemiol, 25, pp.561~568 (2010)
- Huo N, "Sex differences in the association between midlife cardiovascular conditions or risk factors with midlife cognitive decline", Neurology, 98, pp.e623~e632 (2022)
- Mendrek A, "Sex", gender differences in the brain and cognition in schizophrenia, 2016, pp.67, 57~78
- Ran MS, "Gender differences in outcomes in people with schizophrenia in rural China : 14-year follow-up study", Br J Psychiatry, 206, pp.283~288 (2015)
- Dong R, "Sex differences in the association between serum BDNF and cognitive impairment in schizophrenia patients using various antipsychotics", J Psychiatr Res, 138, pp.492~499 (2021)
- Goldstein JM, "Are there sex differences in neuropsychological functions among patients with schizophrenia?", Am J Psychiatry, 155, pp.1358~1364 (1998)
- Kay SR, "The positive and negative syndrome scale(PANSS)for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
- Randolph C, "The repeatable battery for the assessment of neuropsychological status(RBANS) : preliminary clinical validity", J Clin Exp Neuropsychol, 20, pp.310~319 (1998)
- Kahn RS, "Schizophrenia is a cognitive illness : time for a change in focus", JAMA Psychiatry, 70, pp.1107~1112 (2013)
- Zanelli J, "Gender differences in neuropsychological performance across psychotic disorders--a multi-centre population based case-control study", PLoS One, 8, pp.e77318~ (2013)
- Kao YC, "The influence of sex on cognitive insight and neurocognitive functioning in schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 44, pp.193~200 (2013)
- Pu C, "Gender differences of neurocognitive functioning in patients with first-episode schizophrenia in China", Compr Psychiatry, 95, pp.152132~ (2019)
- Wei CW, "Sex differences in the association of body mass index with symptoms and cognitive deficits in Chinese patients with chronic schizophrenia", Transl Psychiatry, 10, pp.18~ (2020)
- Li W, "Sex differences in obesity and cognitive function in Chinese elderly patients with chronic schizophrenia", Front Endocrinol(Lausanne), 13, pp.742474~ (2022)
- Collinson SL, "Brain volume, asymmetry and intellectual impairment in relation to sex in early-onset schizophrenia", Br J Psychiatry, 183, pp.114~120 (2003)
- Haijma SV, "Brain volumes in schizophrenia : a meta-analysis in over 18000 subjects", Schizophr Bull, 39, pp.1129~1138 (2013)
- Türközer HB, "Regional and sex-specific alterations in the visual cortex of individuals with psychosis spectrum disorders", Biol Psychiatry, 92, pp.396~406 (2022)
- Lauriello J, "Similar extent of brain dysmorphology in severely ill women and men with schizophrenia", Am J Psychiatry, 154, pp.819~825 (1997)
- Seeman MV, "Men and women respond differently to antipsychotic drugs", Neuropharmacology, 163, pp.107631~ (2020)
- Bener A, "A two fold risk of metabolic syndrome in a sample of patients with schizophrenia : do consanguinity and family history increase risk?", Diabetes Metab Syndr, 8, pp.24~29 (2014)
- -TRODAT-1 and a meta-analysis, "Schizophr Bull", 2013, 378~386
- Brand BA, "Antipsychotic medication for women with schizophrenia spectrum disorders", Psychol Med, 52, pp.649~663 (2022)
- Henderson DC, "Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses", Lancet Psychiatry, 2, pp.452~464 (2015)
- Elmarakby AA, "Sex differences in hypertension: lessons from spontaneously hypertensive rats (SHR)", Clin Sci(Lond), 135, pp.1791~1804 (2021)
- Colafella KMM, "Sex-specific differences in hypertension and associated cardiovascular disease", Nat Rev Nephrol, 14, pp.185~201 (2018)
- Zhuo C, "Metabolic risk factors of cognitive impairment in young women with major psychiatric disorder", Front Psychiatry, 13, pp.880031~ (2022)
- Bosia M, "Cognition in schizophrenia : modeling the interplay between interleukin-1β C-511T polymorphism, metabolic syndrome, and sex", Neuropsychobiology, 80, pp.321~332 (2021)
- Rubin LH, "Sex difference in cognitive response to antipsychotic treatment in first episode schizophrenia", Neuropsychopharmacology, 33, pp.290~297 (2008)
- Pillinger T, "Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology : a systematic review and network meta-analysis", Lancet Psychiatry, 7, pp.64~77 (2020)
- Fernando P, "Do we need sex-oriented clinical practice guidelines for the treatment of schizophrenia?", Curr Opin Psychiatry, 33, pp.192~199 (2020)
- Seeman MV, "Sex differences in schizophrenia relevant to clinical care", Expert Rev Neurother, 21, pp.443~453 (2021)
- Semaan SJ, "Sexual differentiation and development of forebrain reproductive circuits", Curr Opin Neurobiol, 20, pp.424~431 (2010)
- Varlamov O, "Western-style diet, sex steroids and metabolism", Biochim Biophys Acta Mol Basis Dis, 1863, pp.1147~1155 (2017)
- Monteleone P, "Symptoms of menopause-global prevalence, physiology and implications", Nat Rev Endocrinol, 14, pp.199~215 (2018)
- Lizcano F, "Estrogen deficiency and the origin of obesity during menopause", Biomed Res Int, 2014, pp.757461~ (2014)
- Fader AJ, "Estrogen improves performance of reinforced T-maze alternation and prevents the amnestic effects of scopolamine administered systemically or intrahippocampally", Neurobiol Learn Mem, 69, pp.225~240 (1998)
- Bimonte HA, "Estradiol facilitates performance as working memory load increases", Psychoneuroendocrinology, 24, pp.161~173 (1999)
- Lamar M, "Longitudinal changes in verbal memory in older adults : distinguishing the effects of age from repeat testing", Neurology, 60, pp.82~86 (2003)
- Vaura F, "Genetic, molecular, and cellular determinants of sex-specific cardiovascular traits", Circ Res, 130, pp.611~631 (2022)